美股异动 | 百时美施贵宝(BMY.US)涨5% 公司将继续阿尔茨海默病研究

智通财经
Dec 03, 2025

智通财经APP获悉,周三,百时美施贵宝(BMY.US)涨5%,报50.67美元。消息面上,施贵宝周三表示,将招募更多参与者参加一项晚期试验,以评估Cobenfy治疗阿尔茨海默病痴呆相关精神病的安全性和有效性。该公司表示,在发现少数试验地点与临床研究执行相关的“不规范行为”后作出此决定,这些地点的患者数据将从主要分析中排除。

据了解,Cobenfy目前已获批用于治疗成人精神分裂症,具有成为首个基于毒蕈碱受体激动作用、针对躁动和精神病的新一类药物疗法的潜力。预计ADEPT计划(包括ADEPT-2、ADEPT-1和ADEPT-4)针对阿尔茨海默病相关精神病的其他试验结果将在2026年底揭晓。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10